1994
Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon
Roberts J, Bigelow J, Moore A, Belinson J, Stewart J, Hacker M. Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon. Journal Of Immunotherapy 1994, 15: 53-58. PMID: 8110731, DOI: 10.1097/00002371-199401000-00007.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsNeopterin productionInterleukin-2Killer cellsIntraperitoneal interleukin-2Killer cell phenomenonUrinary neopterin excretionRoute of administrationActivated T cellsPresence of neopterinNumber of cytokinesLack of effectN-acetyl serotoninIncreased SystemicNeopterin excretionOvarian carcinomaT cellsImmune responseClinical administrationNeopterinCytotoxic effectsAdministrationSynthesis inhibitorCell phenomenonCells
1986
Regional fibrosis after intraperitoneal administration of mafosfamide
Roberts J, Newman R, Kimberly P, Hacker M. Regional fibrosis after intraperitoneal administration of mafosfamide. Investigational New Drugs 1986, 4: 61-65. PMID: 2939038, DOI: 10.1007/bf00172019.Peer-Reviewed Original Research
1984
Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice
Roberts J, Hacker M, Newman R, McCormack J, Krakoff I. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. Investigational New Drugs 1984, 2: 215-220. PMID: 6469517, DOI: 10.1007/bf00232354.Peer-Reviewed Original ResearchConceptsBladder toxicityIntraperitoneal administrationAcute bladder toxicityPhosphoramide mustardAZ therapyHepatic fibrosisIntravenous administrationLocal toxicityTherapeutic indexMurine systemAdministrationCyclophosphamide analoguesFurther studiesSpontaneous activationAssociated riskToxicityCyclohexylamine saltFibrosisTherapyMice